Nicotinic Acetylcholine Receptor Transmembrane Mutations Convert Ivermectin from a Positive to a Negative Allosteric Modulator
Authors:
- 1 August 2010
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 78 (2) , 198-204
Abstract
Ivermectin is a macrocyclic lactone that acts as a positive allosteric modulator of α7 nicotinic acetylcholine receptors (nAChRs) but has no modulatory activity on 5-hydroxytryptamine (5-HT) type 3 (5-HT3) receptors. By examining the influence of ivermectin on subunit chimeras containing domains from the nAChR α7 subunit and the 5-HT3A subunit, we have concluded that the transmembrane domains play a critical role in influencing allosteric modulation by ivermectin. A series of mutations located within the α-helical transmembrane domains of the α7 subunit were examined, and seven were found to have significant effects on allosteric modulation by ivermectin. Four mutations (A225D, Q272V, T456Y, and C459Y) caused a significant reduction in the potency of ivermectin as an allosteric potentiator. Compared with wild-type α7 nAChRs, potentiation by ivermectin was reduced dramatically (by 89–97%) by these mutations. Somewhat unexpectedly, three mutations (S222M, M253L, and S276V located in TM1, TM2, and TM3) converted ivermectin from a positive allosteric modulator into an antagonist. Levels of inhibition of 56, 84, and 89% were observed on M253L, S276V, and S222M, respectively. Antagonism by ivermectin was insurmountable and had no effect on EC50 of acetylcholine, indicating that it is acting noncompetitively. The seven mutations that influence allosteric modulation by ivermectin are located near a predicted intrasubunit transmembrane cavity. Computer docking simulations provide support for the hypothesis that ivermectin binds in close proximity to this cavity. We conclude that transmembrane mutations in α7 nAChRs are able to convert ivermectin from a positive to a negative allosteric modulator.Keywords
This publication has 40 references indexed in Scilit:
- Positive Allosteric Modulation of the α7 Nicotinic Acetylcholine Receptor: Ligand Interactions with Distinct Binding Sites and Evidence for a Prominent Role of the M2-M3 SegmentMolecular Pharmacology, 2008
- Potentiation of α7 nicotinic acetylcholine receptors via an allosteric transmembrane siteProceedings of the National Academy of Sciences, 2008
- RIC‐3: a nicotinic acetylcholine receptor chaperoneBritish Journal of Pharmacology, 2008
- An Allosteric Modulator of the α7 Nicotinic Acetylcholine Receptor Possessing Cognition-Enhancing Properties in VivoThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Identification of domains influencing assembly and ion channel properties in α 7 nicotinic receptor and 5-HT3 receptor subunit chimaerasBritish Journal of Pharmacology, 2007
- Galanthamine and Non-competitive Inhibitor Binding to ACh-binding Protein: Evidence for a Binding Site on Non-α-subunit Interfaces of Heteromeric Neuronal Nicotinic ReceptorsJournal of Molecular Biology, 2007
- Channel Opening Motion of α7 Nicotinic Acetylcholine Receptor as Suggested by Normal Mode AnalysisJournal of Molecular Biology, 2006
- RIC-3 Enhances Functional Expression of Multiple Nicotinic Acetylcholine Receptor Subtypes in Mammalian CellsMolecular Pharmacology, 2005
- Refined Structure of the Nicotinic Acetylcholine Receptor at 4Å ResolutionJournal of Molecular Biology, 2005
- Ivermectin, an Unconventional Agonist of the Glycine Receptor Chloride ChannelJournal of Biological Chemistry, 2001